These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27008581)

  • 1. Supported Standing in Boys With Duchenne Muscular Dystrophy.
    Townsend EL; Bibeau C; Holmes TM
    Pediatr Phys Ther; 2016; 28(3):320-9. PubMed ID: 27008581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal health in Duchenne dystrophy: bone-size and subcranial dual-energy X-ray absorptiometry analyses.
    King WM; Kissel JT; Visy D; Goel PK; Matkovic V
    Muscle Nerve; 2014 Apr; 49(4):512-9. PubMed ID: 23893858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How often should sitting and rising from a chair be evaluated in patients with Duchenne muscular dystrophy?
    Hukuda ME; Caromano FA; Escorcio R; Carvalho EV; Blascovi-Assis SM; Voos MC
    Arq Neuropsiquiatr; 2017 Sep; 75(9):625-630. PubMed ID: 28977142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual Reality Computer Gaming with Dynamic Arm Support in Boys with Duchenne Muscular Dystrophy.
    Heutinck L; Jansen M; van den Elzen Y; van der Pijl D; de Groot IJM
    J Neuromuscul Dis; 2018; 5(3):359-372. PubMed ID: 29991140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation scale development, reliability for sitting and standing from the chair for Duchenne muscular dystrophy.
    Hukuda ME; Escorcio R; Fernandes LA; de Carvalho EV; Caromano FA
    J Mot Behav; 2013; 45(2):117-26. PubMed ID: 23488586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of Ankle Plantarflexion Contractures and Functional Decline in Duchenne Muscular Dystrophy: Implications for Physical Therapy Management.
    Kiefer M; Bonarrigo K; Quatman-Yates C; Fowler A; Horn PS; Wong BL
    Pediatr Phys Ther; 2019 Jan; 31(1):61-66. PubMed ID: 30557283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy.
    Vry J; Schubert IJ; Semler O; Haug V; Schönau E; Kirschner J
    Eur J Paediatr Neurol; 2014 Mar; 18(2):140-9. PubMed ID: 24157400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy.
    Lott DJ; Taivassalo T; Cooke KD; Park H; Moslemi Z; Batra A; Forbes SC; Byrne BJ; Walter GA; Vandenborne K
    Muscle Nerve; 2021 Mar; 63(3):320-326. PubMed ID: 33295018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.
    Jansen M; de Groot IJ; van Alfen N; Geurts ACh
    BMC Pediatr; 2010 Aug; 10():55. PubMed ID: 20691042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: A preliminary report.
    Al-Zougbi A; Mathews KD; Shibli-Rahhal A
    Muscle Nerve; 2019 Apr; 59(4):422-425. PubMed ID: 30636004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle function and age are associated with loss of bone mineral density in Duchenne muscular dystrophy.
    Del Rocío Cruz-Guzmán O; Rodríguez-Cruz M; Almeida-Becerril T; Maldonado-Hernández J; Baeza CW
    Muscle Nerve; 2019 Apr; 59(4):417-421. PubMed ID: 30623456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.